Optimizing Pharmaceutical Synthesis: The Role of CAS 163521-11-7
In the intricate process of pharmaceutical synthesis, the quality and availability of intermediate compounds directly impact the efficiency and success of the entire operation. Ethyl 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-2-benzofurancarboxylate, known by its CAS number 163521-11-7, is one such indispensable intermediate. Its primary application lies in the synthesis of Vilazodone, a crucial medication for managing major depressive disorder. For manufacturers aiming to produce Vilazodone reliably and cost-effectively, securing a stable supply of this high-purity chemical intermediate is a strategic imperative.
When considering the procurement of CAS 163521-11-7, focusing on manufacturers in China offers a significant advantage. These suppliers are known for their advanced synthesis capabilities and stringent quality control measures, ensuring that the product meets the demanding standards of the pharmaceutical industry. The typical description of this compound as a light yellow to off-white powder with a purity of NLT 98% underscores its suitability for sensitive chemical reactions. Its molecular formula, C28H30N4O3, and molecular weight of 470.56 g/mol are critical data points for process chemists and formulation scientists.
Optimizing pharmaceutical synthesis with CAS 163521-11-7 involves not only sourcing the material but also understanding its handling and integration into the manufacturing workflow. Factors like proper storage (2-8°C) and adherence to safety guidelines are essential. By partnering with established suppliers, companies can ensure timely delivery and access to necessary technical documentation, including Certificates of Analysis. For those looking to purchase this crucial component, researching manufacturers and comparing pricing for bulk orders can lead to considerable savings, further enhancing the cost-efficiency of Vilazodone production. The strategic sourcing of this pharmaceutical intermediate from China is a key element in streamlining the development and manufacturing of essential medicines.
When considering the procurement of CAS 163521-11-7, focusing on manufacturers in China offers a significant advantage. These suppliers are known for their advanced synthesis capabilities and stringent quality control measures, ensuring that the product meets the demanding standards of the pharmaceutical industry. The typical description of this compound as a light yellow to off-white powder with a purity of NLT 98% underscores its suitability for sensitive chemical reactions. Its molecular formula, C28H30N4O3, and molecular weight of 470.56 g/mol are critical data points for process chemists and formulation scientists.
Optimizing pharmaceutical synthesis with CAS 163521-11-7 involves not only sourcing the material but also understanding its handling and integration into the manufacturing workflow. Factors like proper storage (2-8°C) and adherence to safety guidelines are essential. By partnering with established suppliers, companies can ensure timely delivery and access to necessary technical documentation, including Certificates of Analysis. For those looking to purchase this crucial component, researching manufacturers and comparing pricing for bulk orders can lead to considerable savings, further enhancing the cost-efficiency of Vilazodone production. The strategic sourcing of this pharmaceutical intermediate from China is a key element in streamlining the development and manufacturing of essential medicines.
Perspectives & Insights
Future Origin 2025
“For manufacturers aiming to produce Vilazodone reliably and cost-effectively, securing a stable supply of this high-purity chemical intermediate is a strategic imperative.”
Core Analyst 01
“When considering the procurement of CAS 163521-11-7, focusing on manufacturers in China offers a significant advantage.”
Silicon Seeker One
“These suppliers are known for their advanced synthesis capabilities and stringent quality control measures, ensuring that the product meets the demanding standards of the pharmaceutical industry.”